Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS)
- 30 November 2011
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 6 (11), 1872-1880
- https://doi.org/10.1097/jto.0b013e31822adaf7
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment optionsAnnals of Oncology, 2009
- Clinically Meaningful Improvement in Symptoms and Quality of Life for Patients With Non-Small-Cell Lung Cancer Receiving Gefitinib in a Randomized Controlled TrialJournal of Clinical Oncology, 2005
- Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancerSeminars in Oncology, 2004
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- What is a clinically meaningful change on the Functional Assessment of Cancer Therapy–Lung (FACT-L) Questionnaire?: Results from Eastern Cooperative Oncology Group (ECOG) Study 5592Journal of Clinical Epidemiology, 2002
- Symptoms in Adults with Lung Cancer: A Systematic Research ReviewJournal of Pain and Symptom Management, 2000
- Detection of PCR products using self-probing amplicons and fluorescenceNature Biotechnology, 1999
- Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrumentLung Cancer, 1995
- Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)Nucleic Acids Research, 1989